Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Day One Biopharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 8-K Investor presentation
Docs: "Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience",
"Corporate Presentation"
08/07/2023 8-K Investor presentation, Quarterly results
Docs: "Day One Reports Second Quarter 2023 Financial Results and Corporate Progress Results from FIREFLY-1 demonstrate overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma evaluable patients presented at the 2023 American Society of Clinical Oncology Annual Meeting Initiated rolling submission of the tovorafenib New Drug Application in relapsed or progressive pediatric low-grade glioma in May 2023 The Company expects to complete the rolling submission of the tovorafenib NDA by October 2023 Completed $172.5 million public offering, strengthening balance sheet and extending cash runway into 2026",
"2 PO QW DAY101 QW"
06/12/2023 8-K Investor presentation
Docs: "Corporate Presentation"
06/07/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement",
"Opinion of Fenwick & West LLP",
"Day One Announces Pricing of Public Offering of Common Stock BRISBANE, Calif., June 6, 2023 - Day One Biopharmaceuticals, Inc. , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the pricing of its underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share. All shares of common stock are being offered by Day One. The gross proceeds to Day One from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $150.0 million. In addition, Day One has granted the underwriters a 30-day option to purchase up to an additional 1,730,769 shares of..."
06/06/2023 8-K Other Events  Interactive Data
05/01/2023 8-K Investor presentation, Quarterly results
Docs: "Day One Reports First Quarter 2023 Financial Results and Corporate Progress FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting Leadership team strengthened with executive appointments in clinical development and commercialization Pre-New Drug Application meeting held April 19, 2023 with U.S. Food and Drug Administration for tovorafenib for relapsed or progressive pediatric low-grade glioma Company to host conference call on June 4th at 6:00 PM CT",
"2 PO QW DAY101 QW"
04/20/2023 8-K Quarterly results
03/20/2023 8-K Quarterly results
03/06/2023 8-K Investor presentation, Quarterly results
Docs: "Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma Reported topline data in January 2023 from ongoing, pivotal Phase 2 FIREFLY-1 trial demonstrating meaningful responses with tovorafenib in relapsed or progressive pLGG Additional data from FIREFLY-1 planned for presentation at a medical meeting in second quarter of 2023 New Drug Application submission planned for tovorafenib in first half of 2023",
"2 PO QW DAY101 QW"
02/23/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws of Day One Biopharmaceuticals, Inc. (as amended and restated on February 17, 2023)",
"Amended and Restated Bylaws of Day One Biopharmaceuticals, Inc. (as amended and restated on February 17, 2023)"
01/09/2023 8-K Investor presentation
Docs: "Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib in Recurrent or Progressive Pediatric Low-Grade Glioma",
"Corporate Presentation"
11/07/2022 8-K Investor presentation, Quarterly results
Docs: "Day One Reports Third Quarter 2022 Financial Results and Corporate Progress Topline results for full pivotal FIREFLY-1study population with tovorafenib in relapsed or progressive pediatric low-grade glioma are expected in the first quarter of 2023 Strengthened leadership team with key appointments to senior management team and board of directors SOUTH SAN FRANCISCO, Calif., November 7, 2022 – Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced financial results for the third quarter of 2022 and highlighted recent corporate achievements. “Day One’s progress in 2022 has been remarkable. We announced positive interim results from our ...",
"2 PO QW DAY101 QW"
09/12/2022 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Day One Appoints Garry Nicholson as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., September 12, 2022 - Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncology where he led its global oncology franchise. Day One co-founder Julie Grant, who served as board chair since 2021, will continue to serve as a member of the board of directors. “Garry is an accomplished leader in the development and commercialization of ne...",
"Corporate Presentation"
08/04/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/13/2022 8-K Investor presentation
Docs: "Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib in Relapsed Pediatric Low-Grade Glioma",
"FIREFLY-1 Interim Data Presentation"
05/12/2022 8-K Quarterly results
04/13/2022 8-K Investor presentation
Docs: "II BRAF V600E ATP BRAF V600E"
03/07/2022 8-K Quarterly results
01/05/2022 8-K Investor presentation
Docs: "Day One to Present at the 40th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, CA, January 5, 2022 – Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. ET. A live audio webcast of the presentation will be available by visiting the Events & Presentations section of the Company’s website. An archived replay of the webcast will be available for 30 days following the live presentation. Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicat...",
"II BRAF V600E ATP BRAF V600E"
11/08/2021 8-K Quarterly results
Docs: "Day One Reports Third Quarter 2021 Financial Results and Corporate Progress Enrollment Progresses in the Pivotal Phase 2 FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG; Initial Data Expected in 1H 2022 Upcoming CTOS Meeting to Highlight Single Agent Activity of Lead Drug Candidate, DAY101, in Spindle Cell Carcinoma Compassionate Use Case SOUTH SAN FRANCISCO, CA, November 8, 2021 – Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced financial results for the third quarter of 2021 and highlighted recent corporate achievements. “We continue to build momentum in our lead program with the granting of Rare Pediatric Disease..."
11/03/2021 8-K Investor presentation
Docs: "Day One Announces Presentation at 2021 Connective Tissue Oncology Society Virtual Annual Meeting  Compassionate use case of DAY101 demonstrates a complete response in a pediatric patient with a recurrent spindle cell sarcoma harboring a BRAF gene fusion SOUTH SAN FRANCISCO, CA, November 3, 2021 – Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced an upcoming poster presentation at the 2021 Connective Tissue Oncology Society Virtual Annual Meeting, being held from November 10-13, 2021. The poster reviews a compassionate use case of a child with recurrent spindle cell sarcoma harboring a novel SNX8-BRAF gene fusion who had exha...",
"2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 NH2 COOH BRAF"
08/17/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy